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H I G H L I G H T S
• COPD is related to calcifications in the extracranial arteries.• COPD may affect atherosclerosis in various vessel beds differently.• COPD is related to arterial calcification independent of smoking.
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A B S T R A C T
Background and aims: COPD is associated with an increased risk of cardiovascular morbidity and mortality,
potentially by mechanisms of atherosclerosis. Insight into location-specific vulnerability to atherosclerosis in
COPD, including intracranial arteries, is lacking. We aimed to investigate the relation between COPD and
atherosclerosis in multiple vessel beds within a large population-based cohort study.
Methods: From 2003 to 2006, a random sample of 2187 elderly participants (mean age, 69.6 ± 6.8 years;
50.9% female; 11.7% COPD) from the population-based Rotterdam Study underwent computed tomography to
quantify atherosclerotic coronary artery calcification (CAC), aortic arch calcification (AAC), extracranial carotid
artery calcification (ECAC), and intracranial carotid artery calcification (ICAC). We investigated the association
of COPD [ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC) < 70%] with
the presence of calcification and with calcification volumes in each vessel bed using logistic and linear re-
gression, with adjustments for cardiovascular risk factors including smoking.
Results: The prevalence of CAC, AAC and ECAC was significantly higher in subjects with COPD compared to
those without. After adjusting for age and smoking, COPD remained associated with the presence of ECAC (odds
ratio 1.46 [95% confidence interval, 1.02–2.07, p=0.037]). COPD was significantly associated with larger
calcification volumes in all four vessel beds in people in whom calcification was present.
Conclusions: The results of this study suggest that COPD plays a role in extracranial carotid artery atherosclerosis
initiation and systemic atherosclerosis aggravation.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is an important
contributor to global morbidity and mortality [1,2]. In addition to its
direct effect on mortality due to lung disease, COPD is also associated
with an increased risk of cardiovascular morbidity and mortality [3–6].
From a clinical point-of-view, there is a need to identify as early as
possible those persons with COPD that are at highest risk of
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cardiovascular events. Atherosclerosis may play a crucial role in the
link between COPD and cardiovascular morbidity and mortality
[3–5,7–9]. Studies have identified a high burden of atherosclerotic
calcifications in multiple extracranial vessel beds in persons with COPD,
independent of smoking [10–13]. Insight into whether COPD is also
associated with aggravated atherosclerosis in intracranial vessels would
be valuable. Previous longitudinal analyses showed higher cardiac risk
estimates than stroke risk estimates for subjects with COPD compared
to subjects without COPD [4,14]. We therefore hypothesized that per-
sons with COPD present with a location-specific vulnerability to
atherosclerosis, with smaller estimates of atherosclerosis in the in-
tracranial vessel beds.
We aimed to examine the burden of atherosclerosis in persons with
COPD in different vessel beds, including extracranial and intracranial
vessels. To this end, we investigated the prevalence and volumes of
atherosclerotic calcifications in subjects with COPD and subjects
without COPD from a large, prospective population-based cohort study
of middle-aged and elderly persons.
2. Patients and methods
2.1. Setting
This study is embedded within the prospective, population-based
Rotterdam Study [15]. Between 2003 and 2006, all participants that
visited the research center were invited to undergo multi-detector
computed tomography (MDCT) to quantify the amount of athero-
sclerotic calcification in multiple vessel beds. In total, 2524 participants
were scanned (Fig. 1). Due to the presence of image artefacts, coronary
stent implantations or pacemakers, 111 CT examinations could not be
graded for vascular calcification in at least one of the vessel beds,
leaving 2413 participants with a complete CT-examination. Compar-
ison of baseline characteristics between persons with complete CT ex-
amination and those with no or incomplete CT examination has been
described previously [16,17]. In addition, these participants underwent
spirometry to assess the presence of COPD.
The Rotterdam Study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki and has been approved by the medical
ethics committee according to the Population Screening Act: Rotterdam
Study, executed by the Ministry of Health, Welfare and Sports of the
Netherlands. All participants provided written informed consent.
2.2. COPD assessment
Spirometry was performed using a portable spirometer (SpiroPro;
Erich Jaeger GmbH; Hoechberg, Germany) by trained paramedical
personnel according to the ATS/ERS guidelines [18,19]. Reversibility
tests were not performed in this population-based setting, however,
participants with physician-diagnosed asthma were excluded [20]. The
diagnosis and classification of COPD were based on the Global initiative
for chronic Obstructive Lung Disease (GOLD) criteria [proportion of the
forced vital capacity exhaled in the first second (FEV1/FVC) < 70%],
with distinction of mild (FEV1 ≥80%), moderate (FEV1≥50 and
FEV1<80%), and severe COPD (FEV1<50%) [7,21]. In the absence
of an interpretable spirometry within the Rotterdam Study, cases were
defined as having COPD diagnosed by a physician on the basis of
clinical presentation and obstructive lung function measured by the
general practitioner or respiratory physician [22].
2.3. Assessment of atherosclerotic calcification
Non-contrast MDCT examinations were performed using a 16-slice
(n= 785) or 64-slice (n=1739) CT scanner (Somatom Sensation16 or
64; Siemens, Forchheim, Germany). The usage of the 16 slice CT versus
64 slice CT was not significantly differentially distributed between
COPD and non-COPD subjects. Detailed imaging parameters can be
found elsewhere [23]. In short, we acquired a cardiac scan and a scan
that reached from the aortic arch to the intracranial vasculature (1 cm
above the sella turcica) to obtain information on calcification in the
coronary arteries, aortic arch, extracranial carotid arteries, and in-
tracranial carotid arteries (Fig. 2).
Coronary artery calcification (CAC), aortic arch calcification (AAC),
and extracranial carotid artery calcification (ECAC) were quantified by
calculating the volume using commercially available software
(Syngo.via CalciumScoring; Siemens) [23,24]. For intracranial carotid
artery calcification (ICAC), we used a semi-automated scoring method
Fig. 1. Flowchart of the study population.
AAC: aortic arch calcification, CAC: coronary artery calcification, COPD:
chronic obstructive pulmonary disease, ECAC: extracranial carotid (EC) artery
calcification, ICAC: intracranial carotid (IC) artery calcification, MDCT: multi-
detector computed tomography (CT).
Fig. 2. Arterial calcifications in different vessel beds visible on MDCT-images.
AAC: aortic arch calcification, CAC: coronary artery calcification, ECAC: ex-
tracranial carotid (EC) artery calcification, ICAC: intracranial carotid (IC) artery
calcification, MDCT: multi-detector computed tomography (CT).
L. Lahousse, et al. Atherosclerosis 291 (2019) 107–113
108
that is described in detail elsewhere [17,25]. All calcification volumes
are expressed in mm3.
2.4. Other covariables
Information on cardiovascular risk factors was obtained by inter-
view, physical examination and blood sampling [15]. Body mass index
(BMI) was calculated as weight/height in m2. Systolic and diastolic
blood pressures were measured twice at the right arm using a random
zero sphygmomanometer and the mean of these measurements was
used in the analyses. Arteriolar oxygen saturation was the average of
the 2 measurements (with increments of 0.5% points) with a pulse
oximeter (Oxycount; Andos, Hamburg, Germany) on the right index
finger. Serum total cholesterol and high-density lipoprotein (HDL)
cholesterol were determined in fasting blood samples using an auto-
matic enzymatic procedure (Hitachi analyser, Roche Diagnostics). In
addition, glucose was determined in blood samples obtained at the
research center. Diabetes mellitus was defined as blood glucose-low-
ering medication use and/or a non-fasting serum glucose level of
≥11.1 mmol/L and/or fasting serum glucose levels ≥7mmol/L. In-
formation on smoking behaviour was collected using home interviews.
Smoking status was self-reported and classified as current if subjects
were still smoking at the time of the examination, past if they had quit
smoking, or never. Cigarette pack years were computed as duration of
smoking (years) multiplied by the number of smoked cigarettes, divided
by 20. We assessed information on use of blood pressure-lowering
medication, anti-diabetic medication and lipid-lowering medication by
interview.
2.5. Statistical analyses
Differences in baseline characteristics between persons with and
without COPD were studied using Student's t-test or Mann-Whitney U
test for continuous variables and Chi-Square test for categorical
variables. Wilson score method for a binomial proportion was used to
calculate prevalence plus 95% confidence intervals. We investigated the
distribution of calcification in the four vessel beds in persons without
and with COPD (by quartiles of calcification). We used logistic regres-
sion models to investigate the association between COPD and presence
of calcification in the different vessel beds. Adjustments were made for
all non-collinear potential confounders if they changed the risk estimate
by more than 10%. Age, sex, body mass index (BMI), height, weight,
smoking behaviour, systolic blood pressure, diastolic blood pressure,
hypercholesterolemia [total serum cholesterol, high-density lipoprotein
(HDL)-cholesterol], diabetes mellitus, and use of antihypertensives and
lipid-lowering drugs were considered as potential confounders. An ad-
ditional sex-stratified analysis was performed. Next, we used linear
regression analyses to investigate associations of COPD and calcifica-
tion volume per vessel bed in the persons with calcification. Because of
the right-skewed distribution of calcification volume, values were nat-
ural log-transformed and 1.0 mm³ was added to the non-transformed
values to deal with calcium volumes of zero (Ln[calcificationvolume
+1.0 mm³]). All non-collinear potential confounders were modelled in
a linear regression model with stepwise backward selection. Statistical
analyses were performed using SPSS, version 23.0 for Windows (IBM,
North Castle, NY).
3. Results
3.1. Population for analysis
Of 2413 participants with a complete CT-examination, 226 subjects
were excluded due to a confirmed or suspected diagnosis of asthma.
Among the 2187 included subjects, 256 had COPD and 1931 subjects
had no COPD at the time of the scan. Baseline characteristics of the
study population are presented in Table 1. COPD subjects were slightly
older, more often male and more frequently smokers.
Table 1
Baseline characteristics of the study population (n= 2187).
COPD
(n= 256)
Controls
(n= 1931)
p-value
Age (years) 69.8 (10.9) 67.8 (9.5) 0.00021
Males 146 (57.0) 928 (48.1) 0.007
Body mass index (kg/m2) 26.5 (4.8) 27.1 (4.8) 0.008
Height (cm) 169.3 (13.3) 167.8 (13.8) 0.00047
Weight (kg) 77.2 (18.0) 77.0 (18.0) 0.844
Smoking status: 2.1 E−14
Never smoking 44 (17.2) 662 (34.3)
Past smoking 144 (56.3) 1056 (54.7)
Current smoking 68 (26.6) 213 (11.0)
Pack years 24.9 (37.9) 4.9 (23.0) 7.5 E−20
Diabetes mellitus 48 (19.6) 218 (12.0) 0.001
Total cholesterol (serum, mmol/l) 5.5 (1.4) 5.7 (1.2) 0.00022
HDL-cholesterol (serum, mmol/l) 1.3(0.5) 1.4 (0.5) 0.044
Systolic blood pressure (mmHg) 147.0 (29.5) 144.5 (25.0) 0.627
Diastolic blood pressure (mmHg) 78.5 (15.8) 80.5 (14.0) 0.028
Blood pressure lowering medication 111 (44.2) 724 (38.1) 0.060
Serum lipid reducing agents 60 (23.9) 429 (22.6) 0.632
FEV1 (% predicted) 81.6 (27.5) 109.3 (24.1) 3.3 E−48
FEV1/FVC (%) 65.5 (7.7) 77.5 (7.1) 2.2 E−35
CAC (%) 227 (88.7) 1561 (80.8) 0.002
AAC (%) 246 (96.1) 1775 (91.9) 0.018
ECAC (%) 212 (82.2) 1390 (72.0) 0.00024
ICAC (%) 217 (84.8) 1577 (81.7) 0.225
AAC: aortic arch calcification, CAC: coronary artery calcification, COPD: chronic obstructive pulmonary disease, ECAC: extracranial carotid (EC) artery
calcification, FEV1: forced expiratory volume in 1 s, FEV1/FVC: proportion of the forced vital capacity exhaled in the first second, HDL: high-density
lipoprotein, ICAC: intracranial carotid (IC) artery calcification. Categorical variables are expressed as numbers (percentage). Values of continuous vari-
ables are expressed as median (IQR). Pack years were missing in 15, diabetes status in 126, cholesterol in 35, blood pressure in 8, and drug use in 34
subjects. Spirometry was performed in 2031 subjects (246 with COPD and 1785 controls), results were comparable though only presented for interpretable
measurements.
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3.2. Relation between COPD and prevalence of atherosclerotic calcification
Atherosclerotic calcification in the coronary arteries was present in
1788 subjects, in the aortic arch in 2021 subjects, in extracranial car-
otid arteries in 1602 subjects, and in intracranial carotid arteries in
1794 subjects (Fig. 1). The crude prevalence of CAC, AAC, and ECAC
was significantly higher in subjects with COPD compared to those
without COPD (88.7% vs. 80.8% (p=0.002); 96.1% vs. 91.9%
(p=0.018), and 82.8% vs. 72.0% (p < 0.001), respectively). The
prevalence of ICAC was also higher in subjects with COPD (84.8% vs.
81.7%), although not statistically significant (p=0.225). Table 2
shows logistic regression analyses of COPD on the presence of calcifi-
cation in the different vessel beds. After adjustment for potential
confounders, we observed that COPD was associated significantly with
the presence of ECAC only [odds ratio (OR) 1.46 (95% confidence in-
terval (CI): 1.02; 2.07, p=0.037 adjusted for age and smoking)]. Sex-
stratified analyses are presented in Supplementary Table 1. Fig. 3 shows
the presence of atherosclerotic calcification according to the severity
lung function impairment.
3.3. Relation between COPD and calcification volumes
Within subjects with presence of atherosclerotic calcification in the
coronary arteries (n=1788), aortic arch (n=2021), extracranial
carotid arteries (n=1602) and intracranial carotid arteries (n= 1794),
COPD was associated with larger volumes of atherosclerotic calcifica-
tion in the respective vessel bed (unadjusted p=0.006, p < 0.001,
p < 0.001 and p < 0.001 respectively). Quartiles of calcification ac-
cording to COPD status are presented in Supplementary Table 2.
Table 3 demonstrates that in the final step of linear regression models,
including all non-collinear potential confounders, COPD was sig-
nificantly associated with larger volumes of atherosclerotic calcification
in the different vessel beds (multi-adjusted p=0.013, p < 0.001,
p < 0.001 and p=0.038 respectively). In line, the severity of airflow
limitation (decreased FEV1) was significantly associated with the
atherosclerotic calcification volumes in the four vessel beds (p < 0.001
Pearson Correlation).
4. Discussion
In this large population-based cohort study, we demonstrated a high
prevalence of atherosclerotic calcification in all four major vessel beds
(CAC, AAC, ECAC and ICAC) in an elderly population. We showed that
COPD is, independent of smoking, associated with the presence of
atherosclerotic calcification in extracranial vessel beds, but not in the
Table 2
Logistic regression analyses of COPD on presence of calcification in the different vessel beds.
Coronary artery calcification Aortic arch calcification Extracranial carotid artery calcification Intracranial carotid artery calcification
OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value OR (95%CI) p-value
COPD
Model 1a 1.59 (1.05; 2.40) 0.029 1.85 (0.95; 3.57) 0.069 1.63 (1.15; 2.32) 0.006 1.11 (0.77; 1.60) 0.592
Model 2b 1.57 (1.04; 2.39) 0.034 1.76 (0.91; 3.42) 0.094 1.61 (1.13; 2.29) 0.008 1.08 (0.75; 1.56) 0.690
Model 3c 1.39 (0.91; 2.12) 0.128 1.52 (0.78; 2.96) 0.222 1.46 (1.02; 2.07) 0.037 0.98 (0.66; 1.45) 0.978
CI: confidence interval, COPD: chronic obstructive pulmonary disease.
a Model 1 is adjusted for age and sex.
b Model 2 is adjusted for age, sex and presence of calcification in the other vessel beds.
c Model 3 is adjusted for all non-collinear confounders which changed the risk estimate by more than 10%, i.e. age and smoking status in all models and
additionally sex and height in the CAC model; and sex, height, diastolic blood pressure, antihypertensives and antidiabetics in the ICAC model.
Fig. 3. Prevalence of atherosclerotic calcification according to the severity of
lung function impairment.
COPD: chronic obstructive pulmonary disease, mild COPD: FEV1 ≥80%,
moderate COPD: FEV1≥50 and FEV1<80%, severe COPD: FEV1<50%.
Table 3
Linear regression analyses of COPD on calcification volumes in the different vessel beds.
Coronary artery calcification Aortic arch calcification Extracranial carotid artery calcification Intracranial carotid artery calcification
β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value β (95%CI) p-value
COPD
Model 1a 0.42 (0.16; 0.67) 0.001 0.61 (0.39; 0.84) 1.1E-7 0.58 (0.35; 0.81) 9.6 E−7 0.31 (0.13; 0.50) 0.001
Model 2b 0.08 (−0.14; 0.30) 0.493 0.33 (0.14; 0.53) 0.001 0.33 (0.13; 0.52) 0.001 0.02 (−0.14; 0.18) 0.851
Model 3c 0.33 (0.07; 0.59) 0.013 0.44 (0.21; 0.67) 0.00019 0.44 (0.21; 0.67) 0.00022 0.20 (0.01; 0.39) 0.038
Betas represent the difference in Ln[calcification volume+1] in mm³ for subjects with COPD compared to subjects without COPD.
CI: confidence interval, COPD: chronic obstructive pulmonary disease.
a Model 1 is adjusted for age and sex.
b Model 2 is adjusted for age, sex and calcification volumes in the other vessel beds.
c Model 3 is the final step from the linear regression model including all non-collinear potential confounders with stepwise backward selection, i.e. adjusted for
age, sex, smoking status, diastolic blood pressure, blood pressure-lowering medication in all models and additionally height, diabetes, HDL cholesterol and lipid
lowering drugs in the CAC model; systolic blood pressure, total and HDL cholesterol and lipid lowering drugs in the AAC model; systolic blood pressure and lipid
lowering drugs in the ECAC model; and systolic blood pressure, diabetes, HDL cholesterol and lipid lowering drugs in the ICAC model.
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intracranial carotid vessel beds. In a subset of individuals with calcifi-
cations, COPD was associated with larger volumes of atherosclerotic
calcification in each respective vessel bed.
An important contribution of our study is that our results suggest a
differential role of COPD in the initiation of atherosclerosis in the dif-
ferent vessel beds. COPD was significantly associated with ECAC (OR
1.5) after adjustment for potential confounders, but not with ICAC (OR
1.0). Estimates for AAC (OR 1.5) only reached borderline statistical
significance, and estimates for CAC (OR 1.4) lost statistical significance
after adjustment for potential confounders, likely due to a lack of
power. Our study is the first to identify COPD as a risk factor specific for
extracranial artery atherosclerosis, but not for intracranial carotid ar-
tery atherosclerosis, on a population-based level. A possible explanation
for this finding may be due to the specific pathology of atherosclerosis
in these vessel beds. Atherosclerosis in the extracranial carotid arteries
is thought to be more susceptible to cigarette smoking and systemic
inflammation, whereas atherosclerosis in the intracranial carotid ar-
teries in other studies has been associated with female sex and meta-
bolic syndrome [26–30]. The sex-stratified analysis did not support that
mechanisms underlying intracranial artery atherosclerosis in women in
general would be further aggravated in women with COPD. Given that,
persons with COPD generally have higher levels of circulating leuko-
cytes and inflammatory factors (e.g. C-reactive protein and fibrinogen),
this might partially explain our findings. More evidence for this comes
from a previous study of ours, in which we demonstrated a relation
between COPD and plaques in the extracranial carotid arteries [7]. Yet,
longitudinal research including markers of systemic inflammation is
needed to shed further light on this association.
We also found that, when calcification is present, COPD related to
larger calcification volumes or aggravation of atherosclerosis in each
vessel bed. An interesting hypothesis is that different COPD-related
mechanisms may play a role in plaque initiation compared to plaque
aggravation. Indeed, this study shows that when atherosclerotic disease
is already more advanced – i.e. when calcification is present –, the effect
of COPD on atherosclerotic disease is no longer location-specific, but all
vessel beds are affected.
Interestingly, in all our analyses we adjusted for smoking status
(current, past or never smokers), and still found associations between
COPD and atherosclerosis. In line with our results, others found an
increased susceptibility for asymptomatic atherosclerosis in subjects
with a higher degree of lung function impairment, which was also in-
dependent of smoking [10–13]. Prospectively, CAC was able to identify
subjects at higher risk for COPD independent of smoking [13]. In our
study, estimates for CAC lost statistical significance after adjustment for
potential confounders, likely due to a lack of power. Within the etio-
logical framework of both COPD and atherosclerosis, not only smoking
and ageing, but also inflammation is an important risk factor. Indeed,
differences in aortic calcium scores between subjects with normal and
abnormal spirometry were lower after adjustment for inflammatory
markers in a previous study, advocating a role of systemic inflammation
[31].
From a clinical point of view, our results may be of particular im-
portance in the early identification of COPD patients prone to the co-
occurrence of atherosclerosis. Our results suggest that the screening for
atherosclerosis in persons with COPD may additionally involve imaging
of the extracranial carotid arteries. Especially if the screening for lung
cancer in smokers or the diagnostic work-up of COPD already involves
CT-chest imaging, it may be considered to extend the CT examination to
the extracranial carotid arteries. Another valuable advantage of chest-
CT is that CAC may be directly evaluated. Quantification of CAC has
already proven to be useful in the decision making process for statin
and aspirin therapy in primary prevention [32–35], and as a predictor
of future cardiovascular events and deaths in subjects with COPD [36].
In combination with the assessment of ECAC, one may then estimate
the risk of cardiovascular events more precisely using a single CT-ex-
amination (both for stroke and coronary heart disease) [37,38]. Yet,
although our results give thought to new possibilities for strategies as
described above, the potential benefits, harms and costs should be
carefully balanced, before implementation in current clinical practice.
Prospective research in unselected populations is needed to elucidate
the clinical implications of atherosclerotic calcification reported on CT-
chest imaging ordered for other reasons [36].
A potential limitation of this study is that calcification represents
only a part of the atherosclerotic plaque. Non-calcified plaques – which
may be especially affected by COPD – cannot be visualized using non-
enhanced CT, but requires MRI. Nonetheless, the amount of calcifica-
tion has been established as a reliable marker of the total underlying
plaque burden [39]. Second, although inflammation and oxidative
stress are important risk factors for both COPD and atherosclerosis, we
did not have information at the time of the scan on markers of systemic
inflammation in these persons. Third, by means of cross-sectional
analysis we were not able to investigate causality. Longitudinal studies
are warranted to examine causality and to assess the association with
clinical endpoints. Fourth, despite the relatively large sample size of
population-based individuals with CT of all vessel beds in this study, we
acknowledge the limited power with regards to the non-significant
findings. Future research should validate our findings in other (larger)
cohorts.
This study has several strengths. Our study is the first large study to
comprehensively investigate the association of COPD with athero-
sclerotic calcification in different major vessel beds. Previous studies
investigating multiple vessel beds in subjects with and without COPD
were limited in sample (n=1154, n=234 and n=235) size and did
not measure intracranial carotid arteries [10,31,40]. Presence of sig-
nificant associations in the population-based setting of this study im-
plies a possible stronger link in clinical settings, where COPD is often
more severe. Indeed, effect sizes for atherosclerotic risk markers are
known to be larger in moderate-to-severe COPD [8]. Other strengths of
our study include the standardized image-based assessment of athero-
sclerotic calcification as marker of atherosclerosis in multiple vessel
beds and the detailed COPD assessment.
In conclusion, persons with COPD more often have CAC, AAC and
ECAC, and larger volumes of atherosclerotic calcification in all four
major vessel beds (i.e. CAC, AAC, ECAC and ICAC). The presence and
extent of atherosclerosis in extracranial carotid arteries in patients with
COPD might guide clinicians to add visualization of ECAC to CT-chest
imaging to optimally screen vulnerable COPD patients for stroke and
coronary heart disease.
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